ACE and diabetic kidney disease: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs), which are often administered to both diabetic nephropathy and non-diabetic CKD patients, have been established as the recommended treatment agents for non-diabetic nephropathy patients[6], although either ACEIs or ARBs are insufficient for the prevention of progressive renal disease.